+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Sciatica - Epidemiology Forecast-2030

  • ID: 4855544
  • Report
  • July 2020
  • Region: Global
  • 100 pages
  • DelveInsight
The ‘Sciatica - Epidemiology Forecast-2030’ report delivers an in-depth understanding of the disease, historical and forecasted Sciatica epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Sciatica Understanding

Sciatica is a pain in the lower extremity resulting from irritation of the sciatic nerve. The pain of Sciatica is typically felt from the low-back (lumbar area) to behind the thigh and can radiate down below the knee. The sciatic nerve is the largest nerve in the body and begins from nerve roots in the lumbar spinal cord in the low back and extends through the buttock area to send nerve endings down the lower limb. Radiculopathy is sometimes referred to as sciatic nerve pain. Sciatica is an unbearable condition in which the patient experiences pain and/or paresthesia in the supply of the sciatic nerve or linked lumbosacral nerve root. Sciatica is a specific pain that is a direct result of sciatic nerve or sciatic nerve root pathology. The term sciatica is limited to the pain and irritation in nerve roots from L1 to L4 and may also involve related areas. Many times patients and clinicians use Sciatica to describe any pain arising from the lower back and radiating down to the leg.

There are some major risk factors associated with the patient for the initiation of the disease and further progression. Some of them are personal factors which involve that the peak age of the disease occurrence is between 45 and 64 years. Smoking and mental health are not only of the causes but also major factors for the progression of the disease. Occupational factors include strenuous physical activity, for example, frequent lifting, especially while bending and twisting. Driving, including vibration of the whole body can also be one of the minor factors.

Sciatica Epidemiology Perspective

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Prevalence of Sciatica, Diagnosed Prevalence of Sciatica, Cause-specific Diagnosed Prevalence of Sciatica, Gender-specific Diagnosed Prevalence of Sciatica, Age-specific Diagnosed Prevalence of Sciatica, Surgery eligible patient pool of Sciatica scenario of Sciatica in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017 to 2030.

Sciatica Detailed Epidemiology Segmentation
  • The total prevalent population of Sciatica in the seven major markets ranges was 27,022,660 in 2017
  • The publisher has also analyzed the diagnosed prevalent population of lumbar disc herniation. In 2017, the number of diagnosed prevalent cases of lumbar disc herniation was 7,358,250, which will increase in the forecast period.
  • In 2017, it was estimated that 4,802,485 males and 3,373,349 females were found with Sciatica in the United States.
  • In 2017, the surgery eligible patient pool in the US was 1,082,736, which is anticipated to increase in the forecast period.
  • The age-specific prevalence of Sciatica was maximum in the age group 45-54 with 2,043,958 cases in 2017 in the US while the lowest number of cases were found in 18-34 age group with 1,218,199 cases in 2017.
  • In 2017, it was estimated that 4,802,485 males and 3,373,349 females were found with Sciatica in the United States. On the other hand, a similar trend is not observed in EU5, and Japan wherein females are more predominant than males.
Scope of the Report
  • The report covers the descriptive overview of Sciatica, explaining its causes, signs and symptoms, pathophysiology and currently available therapies.
  • The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan.
  • The report assesses the disease risk and burden and highlights the unmet needs of Sciatica.
  • The report provides the segmentation of the disease epidemiology for 7MM by Total Prevalent Cases of Sciatica, Total Diagnosed and Treated Cases of Sciatica.
Report Highlights
  • Eleven-Year Forecast of Sciatica
  • 7MM Coverage
  • Prevalence of Sciatica
  • Diagnosed Prevalence of Sciatica
  • Cause-specific diagnosed prevalence of Sciatica
  • Gender-specific Diagnosed Prevalence of Sciatica
  • Age-specific Diagnosed Prevalence of Sciatica
  • Surgery eligible patient pool of Sciatica
Key Questions Answered
  • What is the disease risk, burden and unmet needs of Sciatica?
  • What is the historical Sciatica patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
  • What would be the forecasted patient pool of Sciatica at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Sciatica?
  • Out of the countries mentioned above, which country would have the highest prevalent population of Sciatica during the forecast period (2020-2030)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2020-2030)?
Reasons to Buy

The Sciatica report will allow the user to -
  • Develop business strategies by understanding the trends shaping and driving the 7MM Sciatica market.
  • Quantify patient populations in the 7MM Sciatica market to improve product design, pricing, and launch plans.
  • The Sciatica epidemiology report and model were written and developed by Masters and PhD level epidemiologists.
  • The Sciatica epidemiology model developed by the publisher is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 11-year forecast period using reputable sources.
Key Assessments
  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population
Geography Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan
Study Period: 2017-2030
Note: Product cover images may vary from those shown
1 Key Insights

2 Executive Summary

3 SWOT Analysis

4 Sciatica Epidemiology Overview at a Glance
4.1 Patient Share (%) Distribution of Sciatica in 2017
4.2 Patient Share (%) Distribution of Sciatica in 2030

5 Disease Background and Overview: Sciatica
5.1 Introduction
5.2 Difference between Sciatica and Lower Back Pain
5.3 Symptoms of Sciatica
5.4 Causes of Sciatica
5.4.1 Spinal Disc Herniation
5.4.2 Spinal Stenosis
5.4.3 Pregnancy
5.4.4 Piriformis syndrome
5.4.5 Osteoarthritis
5.4.6 Spondylosis and spondylolisthesis
5.4.7 Nondiscogenic causes
5.5 Pathophysiology of disk-related Sciatica
5.5.1 Clinical observation
5.5.2 Physiologic Variants of Sciatica
5.6 Pathophysiological Mechanisms in Radicular Pain
5.6.1 Inflammatory mechanism
5.6.2 Immunological mechanism
5.6.3 Compressive mechanism
5.6.4 Lumbar spinal stenosis
5.6.5 Skeletal Causes of Radiculopathy
5.6.6 Lumbar bulging or herniated disc
5.7 Prognosis
5.8 Biomarkers for Sciatica
5.9 Diagnosis of Sciatica
5.9.1 Indicators for Sciatica
5.9.2 Imaging
5.9.3 Selective Nerve Root Block (SRNB)
5.1 Differential Diagnosis
5.11 Clinical Guidelines for the Diagnosis for Sciatica
5.11.1 Clinical guideline for diagnosis for General Practice
5.12 Diagnostic algorithm
5.13 Prevention of Sciatica

6 Recognized Establishments

7 Treatment
7.1 Nonsurgical Treatment for Sciatica
7.1.1 Physical therapy
7.1.2 Psychological therapies
7.1.3 Medications
7.2 Surgical Treatment of Sciatica

8 The American College of Physicians (ACP) Guidelines for the Treatment of Low Back Pain
8.1 Grading the Evidence and Developing Recommendations
8.2 Comparative Benefits of Pharmacologic Therapies
8.3 Comparative Benefits of Nonpharmacologic Therapies
8.4 Recommendations

9 The National Institute for Health and Care Excellence (NICE) Treatment Guidelines

10 Epidemiology and Patient Population
10.1 Key Findings
10.2 Epidemiology Methodology
10.3 7MM Total Prevalent Population of Sciatica

11 Country Wise-Epidemiology of Sciatica
11.1 United States
11.1.1 Assumption and Rationale
11.1.2 Prevalence of Sciatica in the United States
11.1.3 Diagnosed Prevalence of Sciatica in the United States
11.1.4 Cause-specific Diagnosed Prevalence of Sciatica in the United States
11.1.5 Gender-specific Diagnosed Prevalence of Sciatica in the United States
11.1.6 Age-specific Diagnosed Prevalence in the United States
11.1.7 Surgery Eligible Patient Pool in the United States
11.2 EU5 Countries
11.2.1 Assumption and Rationale
11.3 Germany
11.3.1 Prevalence of Sciatica in Germany
11.3.2 Diagnosed Prevalence of Sciatica in Germany
11.3.3 Cause-specific Diagnosed Prevalence of Sciatica in Germany
11.3.4 Gender-specific Diagnosed Prevalence of Sciatica in Germany
11.3.5 Age-specific Diagnosed Prevalence in Germany
11.3.6 Surgery Eligible Patient Pool in Germany
11.4 France
11.4.1 Prevalence of Sciatica in France
11.4.2 Diagnosed Prevalence of Sciatica in France
11.4.3 Cause-specific Diagnosed Prevalence of Sciatica in France
11.4.4 Gender-specific Diagnosed Prevalence of Sciatica in France
11.4.5 Age-specific Diagnosed Prevalence in France
11.4.6 Surgery Eligible Patient Pool in France
11.5 Italy
11.5.1 Prevalence of Sciatica in Italy
11.5.2 Diagnosed Prevalence of Sciatica in Italy
11.5.3 Cause-specific Diagnosed Prevalence of Sciatica in Italy
11.5.4 Gender-specific Diagnosed Prevalence of Sciatica in Italy
11.5.5 Age-specific Diagnosed Prevalence in Italy
11.5.6 Surgery Eligible Patient Pool in Italy
11.6 Spain
11.6.1 Prevalence of Sciatica in Spain
11.6.2 Diagnosed Prevalence of Sciatica in Spain
11.6.3 Cause-specific Diagnosed Prevalence of Sciatica in Spain
11.6.4 Gender-specific Diagnosed Prevalence of Sciatica in Spain
11.6.5 Age-specific Diagnosed Prevalence in Spain
11.6.6 Surgery Eligible Patient Pool in Spain
11.7 United Kingdom
11.7.1 Prevalence of Sciatica in the United Kingdom
11.7.2 Diagnosed Prevalence of Sciatica in the United Kingdom
11.7.3 Cause-specific Diagnosed Prevalence of Sciatica in the United Kingdom
11.7.4 Gender-specific Diagnosed Prevalence of Sciatica in the United Kingdom
11.7.5 Age-specific Diagnosed Prevalence in the United Kingdom
11.7.6 Surgery Eligible Patient Pool in the United Kingdom
11.8 Japan
11.8.1 Assumptions and Rationale
11.8.2 Prevalence of Sciatica in Japan
11.8.3 Diagnosed Prevalence of Sciatica in Japan
11.8.4 Cause-specific Diagnosed Prevalence of Sciatica in Japan
11.8.5 Gender-specific Diagnosed Prevalence of Sciatica in Japan
11.8.6 Age-specific Diagnosed Prevalence in Japan
11.8.7 Surgery Eligible Patient Pool in Japan

12 Appendix

13 Publisher Capabilities

14 Disclaimer

15 About the Publisher
Note: Product cover images may vary from those shown
Adroll
adroll